---
title: "Regeneron Pharmaceuticals veröffentlicht Transkript zur Q4 2025 Earnings Conference Call"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/274855336.md"
datetime: "2026-02-04T18:32:52.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/274855336.md)
  - [en](https://longbridge.com/en/news/274855336.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/274855336.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/274855336.md) | [繁體中文](https://longbridge.com/zh-HK/news/274855336.md)


# Regeneron Pharmaceuticals veröffentlicht Transkript zur Q4 2025 Earnings Conference Call

Regeneron Pharmaceuticals Inc. hat das Transkript der Telefonkonferenz zu den Ergebnissen des vierten Quartals 2025 veröffentlicht. An dem Call nahmen unter anderem der Präsident und Chief Executive Officer, der Chief Scientific Officer, die Executive Vice President Commercial sowie der Chief Financial Officer teil. Während der Konferenz wurden zentrale Themen wie die Geschäftsentwicklung, die aktuellen Finanzergebnisse, der Ausblick auf kommende Entwicklungen sowie regulatorische und wettbewerbsbezogene Aspekte diskutiert. Das Management betonte: „Wir sind weiterhin bestrebt, unsere Innovationsführerschaft auszubauen und nachhaltiges Wachstum zu erzielen.“ Zudem hieß es: „Unsere Pipeline und strategischen Partnerschaften bilden das Fundament für zukünftigen Erfolg.“ Das vollständige Transkript kann über den untenstehenden Link abgerufen werden. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regeneron Pharmaceuticals Inc. published the original content used to generate this news brief on February 04, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md)
- [ProShares Ultra Nasdaq Biotechnology (BIB.US)](https://longbridge.com/en/quote/BIB.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md)
- [Regeneron Pharmaceuticals, Inc. (REGN.US)](https://longbridge.com/en/quote/REGN.US.md)
- [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/en/quote/IBBQ.US.md)
- [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md)
- [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md)
- [Vanguard Health Care ETF (VHT.US)](https://longbridge.com/en/quote/VHT.US.md)
- [Direxion Daily S&P Biotech Bear 3X ETF (LABD.US)](https://longbridge.com/en/quote/LABD.US.md)
- [ARK Genomic Revolution ETF (ARKG.US)](https://longbridge.com/en/quote/ARKG.US.md)
- [ALPS Medical Breakthroughs ETF (SBIO.US)](https://longbridge.com/en/quote/SBIO.US.md)
- [State Street®HlthCrSelSectSPDR®ETF (XLV.US)](https://longbridge.com/en/quote/XLV.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md)
- [iShares US Pharmaceuticals ETF (IHE.US)](https://longbridge.com/en/quote/IHE.US.md)

## Related News & Research

- [Regeneron Gets FDA OK for Extended Eylea HD Dosing](https://longbridge.com/en/news/281556416.md)
- [Cocrystal Pharma's CDI-988 Secures FDA Fast Track Designation To Prevent And Treat Norovirus](https://longbridge.com/en/news/281522861.md)
- [BUZZ-Caribou rises on FDA's regenerative medicine advanced therapy tag for blood cancer therapy](https://longbridge.com/en/news/281186075.md)
- [<![CDATA[Pfizer and BioNTech Pause Covid Vaccine Study Following Low Enrollment Totals ]]>](https://longbridge.com/en/news/281646186.md)
- [Telomir seeks FDA approval for Telomir-1 to treat breast cancer](https://longbridge.com/en/news/281346305.md)